Movement Alert｜SELLAS Life Sciences Group Inc. Falls 14.89% in Regular Trading, All Arbitration Claims Dismissed in Hong Kong Case

Market Focus07-28

On July 28, SELLAS Life Sciences Group Inc. declined 14.89% in regular trading, trading at $9.9/share, with turnover of $46.72 million.

On the news front, Sirnaomics announced that the arbitration case against SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling. All arbitration claims filed by SELLAS were entirely dismissed. Furthermore, SELLAS is required to bear the opposing party's arbitration-related expenses totaling HKD 7.983 million, due for payment by August 7.

The ruling represents a complete legal defeat for SELLAS, eliminating any potential recovery from the dispute while imposing additional financial obligations. SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for multiple cancer indications. Its key pipeline candidates include Galinpepimut-S (GPS) for acute myeloid leukemia, currently in a pivotal Phase 3 REGAL trial, and CDK9 inhibitor SLS009, which recently enrolled its first patient in a Phase 2 first-line AML trial.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1188783220?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 00:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188783220","market":"us","top_or_hot":-1,"title":"Movement Alert｜SELLAS Life Sciences Group Inc. Falls 14.89% in Regular Trading, All Arbitration Claims Dismissed in Hong Kong Case","media":"Market Focus","content":"<p><p>On July 28, SELLAS Life Sciences Group Inc. declined 14.89% in regular trading, trading at $9.9/share, with turnover of $46.72 million.</p><p>On the news front, Sirnaomics announced that the arbitration case against SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling. All arbitration claims filed by SELLAS were entirely dismissed. Furthermore, SELLAS is required to bear the opposing party's arbitration-related expenses totaling HKD 7.983 million, due for payment by August 7.</p><p>The ruling represents a complete legal defeat for SELLAS, eliminating any potential recovery from the dispute while imposing additional financial obligations. SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for multiple cancer indications. Its key pipeline candidates include Galinpepimut-S (GPS) for acute myeloid leukemia, currently in a pivotal Phase 3 REGAL trial, and CDK9 inhibitor SLS009, which recently enrolled its first patient in a Phase 2 first-line AML trial.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SELLAS Life Sciences Group Inc. Falls 14.89% in Regular Trading, All Arbitration Claims Dismissed in Hong Kong Case</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SELLAS Life Sciences Group Inc. Falls 14.89% in Regular Trading, All Arbitration Claims Dismissed in Hong Kong Case\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-28 00:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 28, SELLAS Life Sciences Group Inc. declined 14.89% in regular trading, trading at $9.9/share, with turnover of $46.72 million.</p><p>On the news front, Sirnaomics announced that the arbitration case against SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling. All arbitration claims filed by SELLAS were entirely dismissed. Furthermore, SELLAS is required to bear the opposing party's arbitration-related expenses totaling HKD 7.983 million, due for payment by August 7.</p><p>The ruling represents a complete legal defeat for SELLAS, eliminating any potential recovery from the dispute while imposing additional financial obligations. SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for multiple cancer indications. Its key pipeline candidates include Galinpepimut-S (GPS) for acute myeloid leukemia, currently in a pivotal Phase 3 REGAL trial, and CDK9 inhibitor SLS009, which recently enrolled its first patient in a Phase 2 first-line AML trial.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLS","symbol_name":"SELLAS Life Sciences Group Inc.","start_time":0,"source_url":"","article_id":"1188783220","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188783220","pubTimestamp":1785168593,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 28, SELLAS Life Sciences Group Inc. declined 14.89% in regular trading, trading at $9.9/share, with turnover of $46.72 million.On the news front, Sirnaomics announced that the arbitration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLS":"SELLAS Life Sciences Group Inc."},"translate_title":"走势快讯|SELLAS Life Sciences Group Inc.常规交易跌14.89%，香港案件所有仲裁索赔被驳回","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":1},"content_text":"On July 28, SELLAS Life Sciences Group Inc. declined 14.89% in regular trading, trading at $9.9/share, with turnover of $46.72 million.On the news front, Sirnaomics announced that the arbitration case against SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling. All arbitration claims filed by SELLAS were entirely dismissed. Furthermore, SELLAS is required to bear the opposing party's arbitration-related expenses totaling HKD 7.983 million, due for payment by August 7.The ruling represents a complete legal defeat for SELLAS, eliminating any potential recovery from the dispute while imposing additional financial obligations. SELLAS Life Sciences Group Inc. is a late-stage clinical biopharmaceutical company focused on developing novel therapies for multiple cancer indications. Its key pipeline candidates include Galinpepimut-S (GPS) for acute myeloid leukemia, currently in a pivotal Phase 3 REGAL trial, and CDK9 inhibitor SLS009, which recently enrolled its first patient in a Phase 2 first-line AML trial.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1188783220","isCrawlerRequest":true}